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Introduction
Rapamycin is a potent immunosuppressant that binds tightly
to the FK506-binding protein (FKBP).[1–4] When bound to FKBP,
rapamycin acquires affinity for a region of mammalian target
of rapamycin (mTor) known as the FKBP-rapamycin binding
(FRB) domain.[5–7] Thus, rapamycin can bind two proteins at the
same time and its coupling to the FRB domain is accompanied
by recruitment of FKBP (Figure 1A). The most common form of
FKBP is a 12 kDa cis–trans prolyl isomerase that serves as a
chaperone for newly synthesized polypeptides.[8] Rapamycin
binds within the active site of FKBP and inhibits isomerase ac-
tivity. The other side of rapamycin binds in a cleft between
two helices of FRB, which is an 89-amino acid, classical up–
down four-helix bundle.[9] In the ternary complex, rapamycin
facilitates limited contacts between FRB and FKBP that further
enforce tight binding.[9,10] Because of these interesting binding
characteristics, the FKBP and FRB proteins have been widely
used as research tools.[11–21] In these applications, rapamycin (or
its synthetic derivatives) have been used to control the juxta-
position of target proteins that are expressed as fusions to
FKBP and FRB. This technology arose from versatile earlier
methods that employ chemical inducers of dimerization (CIDs),
such as dimeric versions of FK506, to bring together FKBP
fusion proteins.[22]
During recent attempts to generate an engineered version
of the FRB domain, mutations at three positions within the
ACHTUNGTRENNUNGrapamycin-binding interface (K2095P, T2098L, and W2101F)[23]
were found to supply selective affinity for a detoxified version
of rapamycin, C20-methallylrapamycin (MaRap).[24–26] For clarity,
we apply the single-letter amino-acid code and refer to the
wild-type protein as KTW and the mutant sequence as PLF.
However, because PLF was identified in a screen, it was not
clear if all three mutations are required for MaRap binding. To
examine this, we generated individual point mutations and
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We recently reported that certain mutations in the FK506-rapa-
mycin binding (FRB) domain disrupt its stability in vitro and in
vivo (Stankunas et al. Mol. Cell, 2003, 12, 1615). To determine
the precise residues that cause instability, we calculated the fold-
ing free energy (DG) of a collection of FRB mutants by measuring
their intrinsic tryptophan fluorescence during reversible chaotrop-
ic denaturation. Our results implicate the T2098L point mutation
as a key determinant of instability. Further, we found that some
of the mutants in this collection were destabilised by up to 6 kcal
mol1 relative to the wild type. To investigate how these mutants
behave in cells, we expressed firefly luciferase fused to FRB mu-
tants in African green monkey kidney (COS) cell lines and mouse
embryonic fibroblasts (MEFs). When unstable FRB mutants were
used, we found that the protein levels and the luminescence
ACHTUNGTRENNUNGintensities were low. However, addition of a chemical ligand for
FRB, rapamycin, restored luciferase activity. Interestingly, we
found a roughly linear relationship between the DG of the FRB
mutants calculated in vitro and the relative chemical rescue in
cells. Because rapamycin is capable of simultaneously binding
both FRB and the chaperone, FK506-binding protein (FKBP), we
next examined whether FKBP might contribute to the protection
of FRB mutants. Using both in vitro experiments and a cell-based
model, we found that FKBP stabilizes the mutants. These findings
are consistent with recent models that suggest damage to intrin-
sic DG can be corrected by pharmacological chaperones. Further,
these results provide a collection of conditionally stable fusion
partners for use in controlling protein stability.
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systematically explored how these changes affected binding to
chemical partners. These studies identified the phenylalanine
at residue 2101 as the key determinant of whether a FRB
domain will accept MaRap.[27]
Interestingly, we found that the three mutations in PLF de-
stabilize it relative to KTW. In vitro, PLF is more susceptible to
thermal denaturation and, in cell lines and mouse fibroblasts,
protein fusions to PLF are rapidly degraded compared to KTW
protein fusions.[24] However, addition of rapamycin or MaRap
to cells that express a fusion of PLF to the kinase, GSK3b, re-
stores protein levels and kinase activity.[24] Upon removal of ra-
pamycin or the addition of a competitor, stability is lost and
the protein is degraded. Thus, rapamycin can be used to re-
strict the activity of a PLF-fusion protein to specific periods of
time, a process that we term “chemically inducible stabiliza-
tion”. This method belongs to a growing family of chemically
regulated degradation systems.[12,28–30]
Although inducible stabilization has applications in the
study of protein function, it is unclear whether all three point
mutations in PLF are required to damage stability because
they were not initially selected for this purpose. Thus, we were
interested in studying the origins of instability by assaying the
effects of substitutions at various amino acid positions in FRB.
During the course of this work, we learned that the T2098L
mutation is principally responsible for the instability of PLF
and we also made the surprising observation that some of the
FRB mutants were destabilized by nearly 6 kcalmol1 against
KTW. To examine the impact of this instability in cells, we creat-
ed a fusion between luciferase and the FRB mutants. In this
system, addition of rapamycin recovered luciferase levels. Be-
cause rapamycin forms a ternary complex with FRB and FKBP,
we also examined the contribution of FKBP to the recovery of
unstable PLF mutants. In vitro and in cells, we found that re-
cruitment of FKBP is strongly stabilizing.
Results and Discussion
Three mutations in FRB render
it unstable compared to the
wild type
To confirm the relative stabilities
of KTW and PLF, we purified re-
combinant proteins from bacte-
ria and measured their intrinsic
tryptophan fluorescence during
chaotropic denaturation (Fig-
ure 1B). The folded, wild-type
FRB protein has been reported
to be stabilized against the un-
folded state by approximately
6–8 kcalmol1 [31] and our results
were consistent with these ob-
servations. Moreover, compar-
ing the DG of PLF and KTW re-
vealed that the mutant was de-
stabilized by 3.9 kcalmol1. Thus, consistent with our previous
findings, the three point mutations in PLF that were originally
intended to provide specificity for synthetic rapamycin deriva-
tives have the side effect of destabilizing the protein.
Design of mutations in the rapamycin-binding interface
Amino acids 2095, 2098, and 2101 of FRB are in the rapamy-
cin-binding interface and the W2101F mutation is responsible
for the binding selectivity of PLF for the rapamycin analogue,
MaRap.[27] Therefore, we wondered whether this substitution
also caused the destabilization of PLF. To address this, we gen-
erated the KTF mutant, which has the W2101F mutation but
has the wild-type residues at positions 2095 and 2098. KTF was
subjected to chemical denaturation and the DG value (and the
DDG relative to KTW) was determined (Figure 2B, i). Analysis of
this data suggested that KTF was nearly as stable as KTW
(DDG=0.7 kcalmol1) ; this indicates that the W2101F muta-
tion does not give rise to the instability of PLF. Therefore, dif-
ferent amino acid substitutions must contribute to the instabil-
ity and drug selectivity of PLF. Next, we generated a series of
mutants in which amino acid 2095 was altered. The DG values
for these mutants suggest that the instability of PLF is not en-
gendered by the proline mutation (Figure 2B, i). For example,
the PTF mutant was only mildly destabilized compared to KTW
(DDG=0.5 kcalmol1). This result was surprising, as we initially
considered the K2095P mutation, as a probable helix-breaker,
to be the most dramatic of the three substitutions and there-
fore a likely source for instability. Finally, we examined the
ACHTUNGTRENNUNGcontribution of residue 2098. Interestingly, introduction of
the T2098L point mutation alone (KLW) lowered the DG by
2.1 kcalmol1 (or 55% of the total loss observed in PLF; Fig-
ure 2B, i). This result indicates that the T2098L substitution is
the primary source of instability in PLF and that this residue
has an important role in the folding of FRB.
Figure 1. Three point mutations in FRB destabilize the protein compared to the wild type. A) Schematic of the
ACHTUNGTRENNUNGternary interaction between FKBP and FRB that is mediated by rapamycin. The location of the three mutations
(K2095P, T2098L and W2101F) in the primary sequence of FRB is shown. These residues are located in the region
of FRB that interacts with rapamycin. B) PLF is unstable relative to KTW. A plot of intrinsic tryptophan fluorescence
is shown. Results are representative of at least four independent experiments.
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Computational design of additional mutants
While our results suggest that residues within the rapamycin-
binding region are important determinants of FRB stability, we
also wanted to understand whether mutations in other regions
of the protein would provide unstable derivatives. To explore
this question, we selected additional residues to target using a
computational approach. The protein design module of the
ROSETTA molecular modeling program identifies amino acid
sequences predicted to be most compatible with a given pro-
tein backbone. This program, therefore, permits the evaluation
of the effects of amino acid mutations on protein stability, in
silico.[32–34] In this analysis, the protein backbone arrangement
is held fixed, and the conformations of the altered (and neigh-
boring) residues are determined by using rotamer-based
Monte Carlo optimization. For the FRB domain, the effects of
virtual mutagenesis were assessed for a large number of sub-
stitutions at a collection of amino acid positions. This analysis
yielded tables of the intrinsic folding free energy predicted for
each mutational outcome. From the resulting data tables, the
top ~5% of mutations that predict substantial changes were
selected (Figure 2B). We generated these mutations in the con-
text of PLF to understand whether the alterations would syner-
gize with those within the binding interface. Strikingly, these
changes yielded proteins that vary in intrinsic folding energy
over a range of approximately 6 kcalmol1. Some of the muta-
tions (e.g. , I2111V) produced FRB domains that were similar to
the wild-type in stability, while others (e.g. , R2076A) were
slightly less stable than PLF. Thus, this collection of ~20 mu-
tants provided a spectrum of FRB proteins that varied in intrin-
sic folding energies.
Mutant FRB domains destabilize glutathione S transferase
(GST)
We had previously determined that PLF could be appended to
certain proteins and that the fusion becomes unstable.[24] To
explore whether this was a general property of unstable FRB
mutants, we expressed our collection attached to the C termi-
nus of glutathione S transferase (GST). We again used trypto-
phan fluorescence to monitor protein unfolding and, from this
data, determined the DG and DDG relative to a fusion of KTW
to GST. Similar to what we observed for the free domains, the
fusions varied in DG and these results confirmed that the
T2098L mutation is a key mediator of stability. Interestingly,
the range of DDG observed was less than 5 kcalmol1, com-
pared to 6 kcalmol1 for the free FRB domains (Figure 2B, i).
This result suggests that GST might dampen the effects of tag
instability and minimize the impact of mutations on the overall
free energy. To further explore this relationship, we performed
a crude comparison of the DDG of the free FRB domains and
the corresponding FRB–GST fusions (Figure 3). A roughly linear
relationship was evident, which suggests that the relative sta-
Figure 2. A series of mutations in the FRB domain reveals the origins of PLF instability. A) Replacing each of the individual PLF mutations in FRB suggests that
the T2098L mutation contributes the bulk of the observed instability. B) Collection of mutants and their observed properties. The mutants with changes in
the rapamycin-binding domain are shown on top and those with perturbation in other regions are on the bottom. Results of experiments involving i) mea-
surement of DG by intrinsic tryptophan fluorescence during chemical denaturation, ii) luciferase activity of luciferase-FRB fusions in two different cell lines,
and iii) activation of an FKBP-rapamycin-FRB transcriptional switch in COS cells are shown. A full description of the experimental details can be found in the
Experimental Section. All errors are standard deviation from the mean.
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bility of the FRB tag might be
reliably replicated as part of the
GST fusion.
Fusing PLF to luciferase cre-
ates a useful platform for
studying relative stability in
cells
While measuring the stability of
purified proteins in vitro provid-
ed insight into the source of
stability in FRB proteins, we
sought to correlate these results
with observations from a cell-
based system. Cells provide the
opportunity to study the effects
of destabilizing mutations on
the susceptibility of the protein
to proteolytic degradation and
quality control. Based on our
observations that FRB instability
transferred to GST fusion pro-
teins, we hypothesized that a
fusion to firefly luciferase would
be useful for this purpose. In
this scenario, enzymatic activity
of an unstable fusion between
the FRB domain and luciferase
would be low in the absence of
rapamycin but protein levels
and luminescence would in-
crease with addition of drug. To
explore this concept, the PLF domain was attached at either
the C or N terminus of firefly luciferase. COS1 cells were trans-
fected with these constructs, and luciferase activity was mea-
sured. Consistent with the design, activity was low in the
ACHTUNGTRENNUNGabsence of drug but addition of 5 nm rapamycin resulted in a
concomitant induction of signal and protein levels (Figure 4).
In addition, we found that the fold induction was dependent
on both the amount of vector that was introduced and the
drug concentration. Interestingly, the C- and N-terminal fusions
behaved differently; in the absence of rapamycin, the basal
level of activity of the luciferase–PLF was less than that of the
PLF–luciferase. Rapamycin increased the luciferase activity in
both cases, but the fold change was ninefold for luciferase–
PLF and less than fivefold for PLF–luciferase. This difference
did not reflect differences in binding to rapamycin, because
the EC50 was similar for both (0.97 and 1.2 nm ; Figure 4B).
These results suggest that the luciferase–PLF fusion might be
Figure 3. Relative stability of the free FRB domain is preserved in a GST fu-
ACHTUNGTRENNUNGsion. The DDG of the free FRB domains is shown plotted against the DDG of
the fusion. In both cases, the DDG is obtained by subtracting the DG of the
mutant from that of the wild type, KTW. Results are the average of at least
two independent experiments per-
formed in triplicate each. Error is com-
pounded standard deviation of the
mean and the trendline is the best fit
linear trend.
Figure 4. Luciferase fusions to PLF are unstable and can be rescued by rapamycin. A) Fusions to PLF are unstable.
COS cells were transiently transfected with the indicated amount of vector and the luminescence of lysates mea-
sured (see the Experimental Section). Results are the average of two independent experiments performed in trip-
ACHTUNGTRENNUNGlicate each, and error is standard deviation of the mean. The inset is an anti-FRB Western blot, which shows that
the protein level of the luciferase-PLF fusion is enhanced by the addition of rapamycin. This antibody also reacts
with endogenous mTor, which serves as the loading control. B) Luminescence is dependent on the concentration
of rapamycin. The half-maximal activities mirror published reports for rapamycin efficacy, which suggests that nei-
ther fusion is impaired in binding ability. Results are the average of two independent experiments performed in
triplicate each and error is standard deviation of the mean. C) The folding free energy calculated for each FRB
mutant in vitro can roughly predict the relative stability in cells. Results are the average of two independent ex-
periments performed in triplicate each. Error is compounded standard deviation of the mean. The inset is a similar
analysis performed using the GST-fusion data.
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less stable than the inverse arrangement. Although the origin
of this difference is not yet clear, the luciferase–FRB fusion was
chosen for further investigation.
The DG calculated in vitro predicts stability in cells
To determine the effects of FRB mutants on luciferase stability
in cells, we generated fusions to a set of 20 mutants and
screened these by using the luminescence assay. In these
ACHTUNGTRENNUNGexperiments, the luciferase activity of cells treated with 5 nm
rapamycin was compared to untreated controls and the fold
induction was measured. The constructs were tested in both
COS1 cell lines and mouse embryonic fibroblasts (MEFs) to ex-
plore potential cell-to-cell variations. When linked to luciferase,
these tags provided proteins with an array of sensitivities to ra-
pamycin (see Figure 2B, ii). In general, FRB domains that were
less stable in vitro produced luciferase fusions more responsive
to the addition of rapamycin (Figure 4C). These results support
a hypothesis in which changes to the primary sequence of FRB
that alter the intrinsic folding energy of the domain cause con-
comitant changes in their stability in cells. Moreover, although
the error was high, the DG calculated in vitro was somewhat
predictive of the relative stability in cells.
Binding of rapamycin to FRB mutants is largely unaffected
by the destabilizing mutations
One concern we had about the luciferase experimental plat-
form is that the observed effects on luminescence could reflect
differences in the affinity for rapamycin. Namely, the destabiliz-
ing mutations might disrupt binding to the chemical partner.
To address this, we generated fusions of FRB mutants to the
transcriptional activator domain, VP16. Addition of rapamycin
to cells expressing both an FKBP–GaL4 fusion and the FRB–
VP16 protein causes drug-dependent recruitment of the VP16
domain to DNA, transcriptional activation and expression of a
secreted alkaline phosphatase (SeAP) reporter gene.[27] In this
system, KTW has an EC50 for activation of SeAP production
that resembles the known affinity of the macromolecular inter-
action (both are around 0.8 nm). Thus, as a convienent mea-
sure of relative potency, we followed SeAP levels as a function
of rapamycin concentration to calculate the EC50 for a subset
of FRB mutants (see Figure 2B, iii). Although there were nota-
ble exceptions (e.g. , the EC50 for PTF and ATF were approxi-
mately threefold higher than for the wild type), these results
suggest that a majority of the mutants bind rapamycin with
similar potency. Thus, we conclude that the observed changes
in luciferase activity are principally a result of damage to FRB
stability and not differences in drug binding.
Recruitment of FKBP helps stabilize a FRB mutant
Rapamycin is a bifunctional molecule that can bind to both
FRB and FKBP at the same time. Earlier work suggested that
FKBP might be required for full recovery of PLF’s stability.[24]
However, to explore this mechanism further, we used intrinsic
tryptophan fluorescence to study the denaturation of FRB in
the context of either rapamycin alone, FKBP alone or the com-
bination. Measuring DG in vitro, we confirmed that addition of
rapamycin to the isolated PLF domain improved stability (Fig-
ure 5A). Next, we added equal molar concentrations of FKBP
to PLF in the absence of rapamycin. After subtracting the
signal attributable to FKBP, we noted an apparent increase in
the stability of the FRB domains. This result is consistent with
previous findings that FK506-binding proteins assist in the
folding of some proteins.[35] Because FKBP contributes to for-
mation of the high affinity ternary complex, we wondered if its
proximity would further stabilize mutants. To test this idea, we
pre-incubated FKBP with rapamycin and PLF and then studied
the stability of the system.
We found that the combination of rapamycin and FKBP was
the most protective (Figure 5). This result supports a model in
which formation of the ternary complex (FKBP–rapamycin–
FRB) shields FRB domains from degradation and provides a
profolding environment. Further, because rapamycin inhibits
the prolyl isomerase activity of FKBP, these results also suggest
that enzymatic function is not required for enhanced stability.
Figure 5. FK506-binding protein protects unstable FRB mutants. A) Denatu-
ration curves of PLF mutant protein in the presence of either FKBP alone,
ACHTUNGTRENNUNGrapamycin alone or the combination. Results are representative of two inde-
pendent experiments. B) In COS cells, disrupting FKBP binding with FK506
decreases PLF stability. Results are the average of two independent experi-
ments performed in triplicate each. Error is standard deviation of the mean.
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Rather, it is likely that formation of the tight complex is re-
sponsible for the observed protection of mutants. To explore
this idea in cells, we introduced the luciferase–PLF construct
into COS cell lines and treated them with either rapamycin or
a combination of rapamycin and FK506. FK506 binds with high
affinity to FKBP, but it does not share rapamycin’s affinity for
the FRB domain. Thus, this compound acts as a competitive in-
hibitor of the rapamycin–FKBP interaction. Increasing the rela-
tive dosage of FK506 greatly reduced luminescence (Fig-
ure 5B). This result suggests that disrupting association with
FKBP diminishes the protective effects gained by rapamycin.
Together, these biochemical and cell-based experiments sug-
gest that the ternary complex is effective at insulating unstable
FRB mutants.
Conclusions
Previous work has indicated that three point mutations in the
FRB domain produce a mutant, PLF, that is unstable and prone
to degradation in cell lines and mouse fibroblasts.[12,24] This
property has been used to regulate a PLF-targeted allele of
GSK-3b in mice, and use of this system has given important
ACHTUNGTRENNUNGinsights into the roles of GSK-3b in skeletal development.[36]
Thus, we were interested in exploring the origins of FRB’s sta-
bility in an attempt to expand the utility of this system. From
the relative DG values for various FRB mutants, we conclude
that the T2098L mutation is the key residue involved in desta-
bilizing PLF (Figure 2A).
We recently reported that the identity of residue 2101 deter-
mines the type of rapamycin analogues that are recognized by
a FRB variant.[27] For example, we found that FRB domains with
a phenylalanine in the 2101 position have affinity for MaRap
but not other analogues, such as C16(S)-butylsulfonamido-ra-
pamycin. Conversely, we found that changes to residue 2098
had less impact on selectivity.[27] Combined with the results of
this study, these findings suggest that the stability and selec-
tivity of FRB mutants can be modulated independent of each
other. Specifically, residue 2101 appears to be most important
for selectivity, while amino acid 2098 is a key mediator of sta-
bility. Because FKBP and FRB domains are widely used in bio-
technological applications.[12,13, 18] this property might facilitate
the rational design of FRB mutants with properties (i.e. , specif-
icity, stability) that are desirable for specific applications.
After isolating the key residue that participates in PLF insta-
bility, we became interested in whether point mutations out-
side the rapamycin-binding interface would also impact stabili-
ty. To explore this issue, we used a computational approach to
identify new mutants. Specifically, we used the design capabili-
ties of the ROSETTA protein-modeling program to predict the
effects of a number of proposed amino acid substitutions. This
approach allowed us to focus experimental efforts on a small
set of mutations most likely to disrupt the stability of FRB.
Some of these mutations, such as R2076A, slightly decreased
the stability of PLF. However, these results were often not dra-
matic and many of the mutations had only modest effects on
stability. Based on this limited study, we propose that muta-
tions within the rapamycin-contacting region are better suited
for generating conditional stability. One possible explanation
for this result is that residues in direct contact with the small
molecule are best positioned to undergo dramatic changes in
local environment during binding.
Rapamycin is a bifunctional molecule: it binds both FRB and
FKBP. The affinity of rapamycin for FRB is enhanced by ~2000-
fold when the drug is first bound to FKBP.[10] This enhanced
ACHTUNGTRENNUNGaffinity is likely mediated by favorable protein–protein inter-
ACHTUNGTRENNUNGactions, as seen in the structure determined by crystallogra-
phy.[9,18] This interesting mechanism of binding prompted us to
explore the contribution of FKBP to stabilizing FRB domains.
We found that the interaction with FKBP amplified the protec-
tive effects of rapamycin both in vitro and in cells (see
Figure 5). These results suggest that formation of the ternary
complex is required for full stabilization.
Numerous disorders, such as cystic fibrosis and Gaucher dis-
ease, have been linked to loss-of-function mutations that dis-
rupt the folding and/or trafficking of the mutant protein.[37]
One strategy to combat these pathogenically unfolded pro-
teins is to generate “chemical chaperones” or “pharmacological
chaperones” that bind to and stabilize the protein in its active
conformation.[38–41] Chemical chaperones are typically weak in-
hibitors and they are believed to stabilize their targets by bind-
ing in the active site and providing folding energy. Chemical
chaperones are gathering significant attention as potential
therapeutic agents and recent successes have focused atten-
tion on understanding the mechanisms by which they protect
damaged proteins.[42] Compelling evidence in the Gaucher dis-
ease model has suggested that the intrinsic folding energy of
the disease-causing protein is a good indicator of its activity in
cell-based systems and in patients.[43,44] In those studies, the
relative stability of the target in vitro was found to correlate
with defects in vivo. Further, addition of a chemical chaperone
recovered both biochemical stability in vitro and function in
cells. This conclusion could have some general applicability,
because we found that degradation-prone FRB mutants be-
haved similarly. Specifically, we found that the DG in vitro cor-
related to stability in cells, and a small-molecule ligand could
recover stability in both experimental settings. Thus, these
studies support a model in which binding of a chemical chap-
erone helps template the binding site of unstable proteins and
overcome damage to intrinsic DG caused by mutations.
Experimental Section
Cloning : Point mutations in the FRB sequence were introduced by
Quikchange mutagenesis (Stratagene) using the plasmids pS-Luc-
FRB or pBJ5-FRB-VP16 as templates. Sequences encoding the FRB
mutants were amplified by PCR from the pS-Luc-FRB vector and
ACHTUNGTRENNUNGligated as C-terminal fusions into the BamH1 and EcoR1 sites of
pGEX2t (Amersham Pharmacia). Mutant identities were confirmed
by sequencing. It should be noted that we employed an 89-amino-
acid version of the FRB domain, and it is unclear if our findings are
applicable to the longer version (93 amino acids) used in related
strategies.[13] All the constructs were generated in the same parent
vector and, thus, contain the same promoter and are likely main-
tained at the same copy number. This approach was taken to mini-
mize differences in apparent degradation rate due to relative
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ACHTUNGTRENNUNGexpression levels instead of intrinsic stability. Previous observations
in our laboratories have noted significant effects on relative degra-
dation rate due to differences in expression.
Protein expression and tryptophan fluorescence : GST-FRB pro-
teins were purified from E. coli BL21 and dialyzed into Tris (10 mm,
pH 7.2) with NaCl (150 mm). The pGEX2t vector contains one
unique thrombin-recognition site between the GST and FRB do-
mains, which permits the cleavage of the GST by using the biotiny-
lated thrombin kit (Novagen). Protein concentrations were deter-
mined by Bradford assay with BSA as a standard. The mutant do-
mains were expressed in good yields in bacteria, although many
required immediate use and they degraded upon prolonged stor-
age (JEG, unpublished observation). All proteins were adjusted to
1000 nm in the dialysis buffer before 50 mL aliquots were transfer-
red to CoStar black opaque 96-well plates. To initiate denaturation,
50 mL of 2O GuHCl was added, the solution mixed and incubated
15 min at room temperature. Consistent with previous reports,[31]
denaturation of FRB domains was reversible under these condi-
tions. Tryptophan fluorescence (280 nm/330 nm) was measured in
a SpectraMax M2 (Molecular Devices) at 23 8C. Rapamycin does not
interfere with fluorescence in this region. Fluorescence values at
eleven GuHCl concentrations in triplicate were used to calculate
DG values in PRISM 3 (GraphPad Software) according to previously
described equations.[31, 45] In experiments with FKBP and/or rapamy-
cin present (see Figure 5), FKBP and/or PLF were present at 1 mm
and the final concentration of rapamycin was 10 mm. In parallel
control experiments, the signal corresponding to denaturation of
FKBP was monitored in the absence of FRB protein and this value
was subtracted from the experiments in which both proteins were
included. Rapamycin was added from a 10 mm stock in ethanol
and equivalent levels (0.1%) of solvent were applied to the control
samples.
Molecular modeling : The ROSETTA molecular modeling program
was used essentially as described.[46,47] The crystal structure 2FAP
was used as a template for all the design calculations. The effects
of mutations on the free energy of folding were assessed after op-
timization of side chain conformations with a Monte Carlo rotamer
placement algorithm.
Luciferase stabilization assay: COS1 cells were cultured in Dulbec-
co’s Modified Eagle Medium + 10% fetal calf serum and penicil-
lin/streptomycin at 37 8C and 5% CO2. For transfection experi-
ments, DNA was resuspended in 20 volumes of OptiMEM and
ACHTUNGTRENNUNGvortexed briefly prior to addition of three volumes of FUGENE 6
(Roche). After a 15 min incubation, the mixture was applied drop-
wise to 10 cm plates containing approximately 80% confluent
COS1 cells. The following day, cells were plated into the wells of
24-well culture plates in 500 mL of culture media. Rapamycin was
added after cells regained adherence. 24 h later, cell lysates were
prepared and luciferase assays performed by using the Dual Luci-
ferase Kit (Promega, Madison, WI). Experiments were repeated at
least three times in either duplicate or triplicate wells. The fold in-
duction values were normalized to an internal standard consisting
of Luciferase–PLF-transfected cells treated with rapamycin (5 nm).
Similar conditions were used in experiments that utilized MEFs.[24]
Transcriptional switch SeAP assays : SeAP assays with FRB mu-
tants fused to VP16 were performed as described.[27] Briefly, 1O106
COS cells were transiently transfected by electroporation with 2 mg
of each of three components of a rapamycin-sensitive transcrip-
tional switch: pBJ5-GaL4-FKBP, pBJ5-FRB-VP16, and a GaL4-SeAP re-
porter. Cells were placed in 96-well tissue culture plates and incu-
bated for 24 h prior to addition of rapamycin (serial twofold dilu-
tions, eight concentrations). After an additional 24 h, endogenous
phosphatases were denatured by treatment at 65 8C for 2 h. Addi-
tion of methylumbelliferrylphosphate (50 mL, 1 mm ; Sigma, St.
Louis, MO) in diethanolamine (pH 10) initiated the SeAP assay.
After 16 h at 37 8C, fluorescence was measured at 355/460 nm in a
SpectraMax M2 multimode plate reader (Molecular Devices, Sunny-
vale, CA). From these curves, the rapamycin concentration required
for half-maximal SeAP activity was calculated in PRISM 3 (Graphpad
Software).
Abbreviations
FKBP: human FK506-binding protein 12, FRB: FK506-rapamycin
binding domain, MEM: modified Eagle medium, GST: glutathione S
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